Compugen predictive discovery capabilities for cancer immunotherapy are focused on novel B7/CD28 like immune checkpoints and other immunomodulatory protein candidates.
Immune checkpoints are negative regulators of the immune system, that play critical roles in maintaining self-tolerance, preventing autoimmunity and protecting tissues from immune collateral damage. These immune checkpoints are often "hijacked" by tumors to restrain the ability of the immune system to mount an effective anti-tumor response. Blocking immune checkpoints is thus a promising approach for activating anti-tumor immunity, which has been proven clinically by the success of antibody antagonists of the T cell checkpoints CTLA4, PD-1 and, PD-L1.READ MORE
The immune system is programmed to avoid attacking the body’s own cells and tissues in a mechanism known as self-tolerance. The negative regulators of the immune system, known as immune checkpoints, play a critical role in the maintenance of self-tolerance. In autoimmune diseases self-tolerance is compromised and the immune system mistakenly attacks the body’s own tissues.READ MORE